menu search

Affirm holdings (afrm) gains but lags market: what you should know

Affirm Holdings (AFRM) closed the most recent trading day at $101.16, moving +0.09% from the previous trading session....

December 23, 2021, 7:08 pm

Affirm holdings (afrm) gains but lags market: what you should know

Affirm Holdings (AFRM) closed the most recent trading day at $101.16, moving +0.09% from the previous trading session....

December 23, 2021, 7:08 pm

Affirm holdings (afrm) gains but lags market: what you should know

Affirm Holdings (AFRM) closed the most recent trading day at $101.16, moving +0.09% from the previous trading session....

December 23, 2021, 7:08 pm

Uniqure shares fall after clinical update from huntington's disease gene therapy trial

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...

December 16, 2021, 1:10 pm

Uniqure shares fall after clinical update from huntington's disease gene therapy trial

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...

December 16, 2021, 1:10 pm

Uniqure shares fall after clinical update from huntington's disease gene therapy trial

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130...

December 16, 2021, 1:10 pm

Ebang seeks to diversify but faces delays

Ebang International went public in June 2020, raising $101 million in gross proceeds in a U.S. IPO. The...

December 6, 2021, 1:42 pm

Ebang seeks to diversify but faces delays

Ebang International went public in June 2020, raising $101 million in gross proceeds in a U.S. IPO. The...

December 6, 2021, 1:42 pm

Ebang seeks to diversify but faces delays

Ebang International went public in June 2020, raising $101 million in gross proceeds in a U.S. IPO. The...

December 6, 2021, 1:42 pm

Xyld: the global x s&p 500 covered call etf generating 9% forward yields

XYLD has generated 101 consecutive distributions of income since its inception in June of 2013 by utili...

November 28, 2021, 9:30 am

Xyld: the global x s&p 500 covered call etf generating 9% forward yields

XYLD has generated 101 consecutive distributions of income since its inception in June of 2013 by utili...

November 28, 2021, 9:30 am

Xyld: the global x s&p 500 covered call etf generating 9% forward yields

XYLD has generated 101 consecutive distributions of income since its inception in June of 2013 by utili...

November 28, 2021, 9:30 am

Adma biologics: turning a corner

On November 10th, ADMA reported a great quarter. Revenue grew to $20.68M, up 101.2% y/y, and the Company reached a number of milestones....

November 20, 2021, 2:01 pm

Adma biologics: turning a corner

On November 10th, ADMA reported a great quarter. Revenue grew to $20.68M, up 101.2% y/y, and the Company reached a number of milestones....

November 20, 2021, 2:01 pm

Adma biologics: turning a corner

On November 10th, ADMA reported a great quarter. Revenue grew to $20.68M, up 101.2% y/y, and the Company reached a number of milestones....

November 20, 2021, 2:01 pm

Gr silver mining files resource estimate for plomosas project, which shows 10.3 million silver-equivalent indicated ounces

GR Silver Mining Ltd told investors it has now filed its NI 43 -101 resource estimate for the Plomosas...

October 11, 2021, 7:49 am

Gr silver mining files resource estimate for plomosas project, which shows 10.3 million silver-equivalent indicated ounces

GR Silver Mining Ltd told investors it has now filed its NI 43 -101 resource estimate for the Plomosas...

October 11, 2021, 7:49 am

Gr silver mining files resource estimate for plomosas project, which shows 10.3 million silver-equivalent indicated ounces

GR Silver Mining Ltd told investors it has now filed its NI 43 -101 resource estimate for the Plomosas...

October 11, 2021, 7:49 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am

Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...

October 9, 2021, 11:23 am


Search within

Pages Search Results: